Gilead hepatitis C drug patent faces European challenge
[LONDON] Two international medical humanitarian organisations said on Monday they had challenged the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment.
Sofosbuvir, sold by the US drugmaker as Sovaldi, is transforming the liver-destroying viral disease by offering an effective cure, but Medecins Sans Frontieres (MSF) and Medecins du Monde (MdM) said its high cost was a serious barrier.
The campaigners argue that the patent on the drug is open to challenge because the science behind sofosbuvir is not new.
If the patent challenge is successful, it could make cheaper generic versions of sofosbuvir available in Europe. MSF and MdM said key patents on sofosbuvir had already been revoked in China and Ukraine, and decisions were pending in other countries.
Officials at Gilead were not immediately available to comment.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue